Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TRAIL and anti-tumor responses.

Mahaveer Swaroop Bhojani1, Brian D Rossú, Alnawaz Rehemtulla

  • 1Center for Molecular Imaging, Departments of Radiology, University of Michigan; Ann Arbor, Michigan 48109-0648, USA.

Cancer Biology & Therapy
|September 26, 2003
PubMed
Summary

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows promise for cancer therapy by inducing tumor cell death. Combination therapy may overcome TRAIL resistance in some cancers, with clinical trials pending.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology.

Nature immunology·2026
Same author

Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer.

Molecular cancer therapeutics·2024
Same author

A molecularly engineered lectin destroys EGFR and inhibits the growth of non-small cell lung cancer.

bioRxiv : the preprint server for biology·2024
Same author

A lipid-associated macrophage lineage rewires the spatial landscape of adipose tissue in early obesity.

JCI insight·2023
Same author

Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization.

Aging·2023
Same author

Lung cancer lesion detection in histopathology images using graph-based sparse PCA network.

Neoplasia (New York, N.Y.)·2023

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cancer cell death, offering a strategy against chemotherapy resistance.
  • While TRAIL targets cancer cells, resistance mechanisms in normal and transformed cells are not fully understood.
  • TRAIL's selective toxicity towards cancer cells suggests a high therapeutic index, but resistance limits its use as a single agent.

Purpose of the Study:

  • To explore the therapeutic potential of TRAIL in cancer treatment.
  • To investigate the role of TRAIL in overcoming chemoresistance.
  • To highlight the importance of combination therapy for TRAIL-resistant tumors.

Main Methods:

  • Review of existing literature on TRAIL, its receptors, and signaling pathways.

Related Experiment Videos

  • Analysis of preclinical study results for TRAIL's efficacy.
  • Discussion of clinical trial outcomes and future prospects.

    • Main Results:

    • TRAIL effectively induces tumor-specific apoptosis, potentially overcoming resistance to conventional chemotherapy.
    • Normal cells exhibit resistance to TRAIL, enhancing its therapeutic index.
    • Tumor cell resistance to TRAIL necessitates combination therapy approaches.

    Conclusions:

    • TRAIL is a promising anti-cancer agent, particularly when used in combination therapies.
    • Further clinical trials are crucial to evaluate TRAIL's safety and efficacy.
    • TRAIL-based combination therapies may represent a significant advancement in cancer treatment.